Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Nintedanib by Avalyn Pharma for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease): Likelihood of Approval
Nintedanib is under clinical development by Avalyn Pharma and currently in Phase I for Interstitial Lung Diseases (Diffuse Parenchymal Lung...